MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer
MRI 引导的基于树突状细胞的胰腺癌疫苗免疫治疗
基本信息
- 批准号:9184977
- 负责人:
- 金额:$ 34.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntigen-Presenting CellsAntigensBiodistributionBiological MarkersBiomedical EngineeringCancer Immunology ScienceCell SurvivalCell physiologyClinicalClinical ResearchClinical TrialsContrast MediaCytotoxic T-LymphocytesDendritic Cell TherapyDendritic Cell VaccineDendritic CellsDetectionDiseaseDoseEtiologyExcisionFDA approvedFutureGeneticGoalsHeparinHistologicHomingHumanImageryImaging PhantomsImmunotherapyIn VitroInjection of therapeutic agentKineticsKnowledge DiscoveryLabelLymphoid TissueMagnetic Resonance ImagingMagnetismMalignant NeoplasmsMalignant neoplasm of pancreasMeasurementMeasuresMethodsModelingMonitorMusOperative Surgical ProceduresOutcomePancreatic Ductal AdenocarcinomaPatientsPeripheralPharmaceutical PreparationsPhysicsPropertyProtaminesProtocols documentationRadiology SpecialtyRelaxationSiteTechniquesTimeTransgenic MiceTransgenic OrganismsTreatment EfficacyTreatment outcomeTumor AntigensVaccinationVaccinesbasecancer immunotherapycancer therapycell motilitychemotherapyclinically relevantdosimetryferumoxytolimage guidedimaging biomarkerimaging modalityin vivoindividual patientinsightlymph nodesmigrationmortalitymouse modelnovel strategiesoutcome forecastphantom modelpre-clinicalpredicting responsequantitative imagingtemporal measurementtherapy outcometranslational studytreatment responsetumoruptake
项目摘要
PROJECT SUMMARY
Dendritic Cell (DC) is a newly emerging and potent form of cancer immune therapy. However, the efficacy of
antigen-loaded DCs (DC-vaccines) is strongly influenced by their ability to migrate to peripheral draining lymph
nodes (LNs). Therefore, it is critical to monitor the in vivo biodistribution of DC-vaccines after vaccination in
order to optimize DC therapy for pancreatic cancer. In this study, we propose magnetically labeling DC-
vaccines to permit magnetic resonance imaging (MRI) of their migration to LNs. We will use clinically
applicable approaches combining FDA-approved drugs (ferumoxytol, heparin, and protamine) for magnetic
DC-vaccine labeling, in which magnetic DC-vaccines can be visualized with advanced MRI methods. These
techniques may offer future insights into the dynamics and kinetics of DC migration in vivo and the related
impacts upon therapeutic outcomes in both pre-clinical and clinical research settings. Additional translational
studies should ultimately follow to evaluate the efficacy of these approaches for early prediction of longitudinal
outcomes during DC therapy in a broad range of tumor etiologies.
This project will address the following Specific Aims using KPC transgenic mouse model of pancreatic cancer.
Aim 1: To optimize clinically applicable methods for magnetic-labeling of DC-vaccines and determine the
quantitative imaging properties of these vaccines with in vitro MRI phantom studies; Aim 2: To assess whether
magnetic-labeling of the DC-vaccine permits quantitative in vivo MRI of subsequent migration to the draining
LNs following DC-based vaccination; and Aim 3: To determine whether that MRI monitored DC-vaccine
migration to LNs can predict therapy.
项目摘要
树突状细胞(DC)是一种新兴的、有效的肿瘤免疫治疗形式。然而,
抗原负载的DC(DC疫苗)受其迁移至外周引流淋巴的能力的强烈影响
节点(LN)。因此,关键是监测DC疫苗接种后的体内生物分布,
以优化胰腺癌的DC治疗。在这项研究中,我们提出磁标记DC-
疫苗以允许它们迁移到LN的磁共振成像(MRI)。我们将在临床上
结合FDA批准的药物(ferumoxytol,肝素和鱼精蛋白)用于磁共振成像的适用方法
DC疫苗标记,其中磁性DC疫苗可以用先进的MRI方法可视化。这些
这些技术可能为DC在体内迁移的动力学和动力学以及相关的
在临床前和临床研究环境中对治疗结果的影响。额外的翻译
研究应最终遵循,以评估这些方法的有效性,为早期预测纵向
DC治疗在广泛的肿瘤病因中的结果。
本项目将使用KPC转基因胰腺癌小鼠模型解决以下具体目标。
目的1:优化DC疫苗磁标记的临床应用方法,并确定DC疫苗的免疫原性。
这些疫苗的定量成像特性与体外MRI体模研究;目的2:评估是否
DC疫苗的磁标记允许随后迁移到引流的定量体内MRI
目的3:确定MRI是否监测DC疫苗
迁移到淋巴结可以预测治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhuoli Zhang其他文献
Zhuoli Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhuoli Zhang', 18)}}的其他基金
MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer
MRI 引导的基于树突状细胞的胰腺癌疫苗免疫治疗
- 批准号:
10336295 - 财政年份:2021
- 资助金额:
$ 34.94万 - 项目类别:
MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer
MRI 引导的基于树突状细胞的胰腺癌疫苗免疫治疗
- 批准号:
9982262 - 财政年份:2016
- 资助金额:
$ 34.94万 - 项目类别:
MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer
MRI 引导的基于树突状细胞的胰腺癌疫苗免疫治疗
- 批准号:
9754617 - 财政年份:2016
- 资助金额:
$ 34.94万 - 项目类别:
MRI-Guided Irreversible Electroporation Ablation for Liver Tumors
MRI 引导不可逆电穿孔消融治疗肝脏肿瘤
- 批准号:
9314545 - 财政年份:2015
- 资助金额:
$ 34.94万 - 项目类别:
MRI-Guided Irreversible Electroporation Ablation for Liver Tumors
MRI 引导不可逆电穿孔消融治疗肝脏肿瘤
- 批准号:
8943253 - 财政年份:2015
- 资助金额:
$ 34.94万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 34.94万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 34.94万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 34.94万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 34.94万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 34.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 34.94万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 34.94万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 34.94万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 34.94万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 34.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




